Exploratory Study of Natural Killer Cells in Human Skin

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00824889

Enrollment

Registered

2009-01-19

Start date

2009-02-28

Completion date

2011-11-30

Last updated

2014-08-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atopic Dermatitis, Contact Dermatitis, Graft Versus Host Disease, Lichen Planus, Melanoma, Psoriasis

Brief summary

Natural Killer (NK) cells play a unique role during innate immune responses as they are able to recognize and eliminate, without specific sensitization, tumors, microbe-infected cells as well as allogeneic cells.In a first time, we will characterize the tissue distribution, the phenotype and the effector functions of NK cells present in the human healthy skin.

Detailed description

Then, we will define whether these parameters are qualitatively/ quantitatively modified in the following skin pathologies: a) atopic dermatitis; b) contact dermatitis; c) psoriasis ; d) lichen planus ; e) GVH (graft versus host disease) ; (f) melanoma.

Interventions

OTHERBiopsy and sample of blood

Biopsy and sample of blood

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Age ≥ 18 years. * Consent obtained after healthy donor or patient information. * Patients suffering from one of the following diseases: a) atopic dermatitis ; b) contact dermatitis; c) psoriasis ; d) lichen planus ; e) GVH ; f) melanoma.

Exclusion criteria

* Age below 18, * pregnant or breastfeeding women, * persons under guardianship, persons without social security, prisoners, persons hospitalized without consent on the basis of French laws L. 3212-1 et L. 3213-1. Patients affected by HIV infection, AIDS, Hepatitis A, B or C infection. * Neutropenia \<1000/mm3. * Thrombopenia \<50 000/mm3.

Design outcomes

Primary

Measure	Time frame
In a first time, we will characterize the tissue distribution, the phenotype and the effector functions of NK cells present in the human healthy skin.	12 months

Secondary

Measure	Time frame
To determine whether the eventual modifications detected in skin pathologies are correlated to qualitative/ quantitative alterations of NK cell subsets present in the peripheral blood.	12 months

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026